TPTX News and Press, Turning Point Therapeutics Inc. From 06/03/22

Turning Point Therapeutics Inc ( NASDAQ: TPTX ) jumped 110% after announcing a definitive merger agreement with Bristol Myers Squibb Co ( NYSE: BMY ) . Under the agreement, Bristol Myers Squibb will acquire Turning Point at $76 per share. The Board of Directors of both T...

Shares of Turning Point Therapeutics Inc ( NASDAQ: TPTX ) more than doubled on Friday after Bristol-Myers Squibb Co ( NYSE: BMY ) said it will buy the biotech company for $4.10 billion in cash. Bristol-Myers to pay $76 a share for TPTX The pharmaceutical giant is paying $76 ...

3 Health Care Stocks For Your June 2022 Watchlist With all the back-and-forth in the stock market recently, investors may be looking for more defensive stocks to jump on. Should that be the case, health care stocks would be among the key groups to consider. After all, the indust...

Raymond James has lowered its rating on Bristol Myers Squibb (NYSE:BMY) to Market Perform from Outperform after the pharma giant agreed to acquire the clinical-stage oncology biotech Turning Point Therapeutics (TPTX) for $4.1B in cash. The analyst Dane Leone highlights the potentially limited...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CrowdStrike (NASDAQ: CRWD ) earnings are hitting CRWD stock today. That’s despite it beating EPS and revenue estimates. It also posted positive guidance for its current fiscal year. Source: Michael Vi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Turning Point Therapeutics (NASDAQ: TPTX ) is rising on acquisition news. Bristol-Myers Squibb  (NYSE: BMY ) is buying the company for $76 per share. TPTX’s repotrectinib is a major factor in the...

Gainers: Turning Point Therapeutics (TPTX) +116%. Amylyx Pharmaceuticals (AMLX) +27%. Yumanity Therapeutics (YMTX) +11%. Amarin (AMRN) +9%. Galecto (GLTO) +8%. Losers: Novavax (NVAX) -13%. Rallybio (RLYB) -13%. Invitae (NVTA) -9%. Spruce Bioscience...

Blueprint Medicines (NASDAQ:BPMC) rose 1.2% in premarket trading,  after Bristol Myers (BMY) agreed to acquire Turning Point Therapeutics (TPTX) for over $4B in cash. Stifel said in a note that buy-rated Blueprint (BPMC) came first to mind after Bristol agreed to buy TPTX. Blue...

Bristol Myers Squibb (NYSE:BMY) has entered into an agreement to acquire the clinical-stage precision oncology company Turning Point Therapeutics (TPTX) at a price of $76.00 per share in cash for a total consideration of $4.1B, the companies announced Friday. Turning Point (TPTX) shares have ...

Bristol Myers Squibb (NYSE:BMY) has entered into an agreement to acquire the clinical-stage precision oncology company Turning Point Therapeutics (TPTX) at a price of $76.00 per share in cash for a total consideration of $4.1B, the companies announced Friday. Turning Point (TPTX) shares have ...